AGENTS USED FOR IRON DEFICIENCY

Slides:



Advertisements
Similar presentations
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Advertisements

Copper Humans have copper 2mg/kg of body weight. Cupper intake 2-5 mg/daily. CU is absorbed from stomach & upper small intestine. 80% Of absorbed CU excreted.
Adrianna Machelska. Diseases of blood and hematopoietic system are less known but very important part of medical science. We encounter them every day,
Dr. Soban sadiq. Oral Therapy: Ferrous Sulphate Ferrous Fumarate Ferrous Gluconate Parenteral Therapy: Iron Dextran Iron-sucrose complex Iron sodium.
Anemia in chronic kidney disease
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 55 Anemia Drugs.
Agents Used to Treat Anemias. Anemia Decreased number of circulating red blood cells Decreased hemoglobin = decreased oxygen capacity Many causes. 22.
HEMATOPOIETIC AND ANTI- ANEMIA AGENTS February 18, 2014 Thomas M. Guenthner, PhD 407D, MSB
ANEMIA DRUGS DSN KEVIN DOBI, MS, APRN Copyright © 2014 by Mosby, an imprint of Elsevier Inc. Chapter 54.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 55 Drugs for Deficiency Anemias.
IRON 7 mg/1000 cal in diet; 10% absorbed Heme iron absorbed best, Fe 2+ much better than Fe 3+ –Some foods, drugs enhance and some inhibit absorption of.
Mineral Project By: Michael Arpasi. Question  How do heavy metals (such as mercury, arsenic, and lead) effect humans?
Prepared by: Raed A. AL-Mohiza Directed by: Dr. Hesham Abo-Audah
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Dr. Sarah Zahid PHARMACOLOGICAL MANAGEMENT OF IRON DEFICIENCY ANEMIA.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
Antianemics Prof. Hanan Hagar
Anemias. Body Contents of Iron Structure of Hemoglobin.
Iron Metabolism HMIM224.
Urinary System. Secreted Substances Secreted Substances Hydroxybenzoates Hydroxybenzoates Hippurates Hippurates Neurotransmitters (dopamine) Neurotransmitters.
Factors Affecting Drug Activity Chapter 11 Pages
Causes Blood loss – usually from uterus or GI tract Increased demands such as growth and pregnancy Decreased absorption – post gastrectomy, Coeliac disease.
PHARMACOLOGY I. PRIMARY PROBLEM II. THERAPEUTIC GOALS III. MANAGEMENT
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division, Department of Medicine in King Saud University.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 18 Nonopioid Analgesics: Nonsteroidal Anti-Inflammatory Drugs.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Dr. Sadia Batool Shahid PGT-M-Phil, Pharmacology
 Stored in the body as ferritin  Deficiency result from negative iron balance due to depletion of stores and/or inadequate intake.  Iron deficiency.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Dr. Mohamed M. Ghanem. Definition A deficiency in iron results in the development of anemia (lower than normal number of red blood cells). In iron deficiency.
1 Adverse effect of drugs Excessive Pharmacologic Effects –overdoing the therapeutic effect –Atropine –muscarinic antagonist, desired therapeutic –Effect:
PHARMACOKINETICS Part 3.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 56 Blood-Forming Drugs.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 8 Cephalosporins.
Clinical Application for Child Health Nursing NUR 327 Lecture 3-D.
Metabolism of iron Alice Skoumalová. Iron in an organism:  total 3-4 g (2,5 g in hemoglobin)  heme, ferritin, transferrin  two oxidation states: Fe.
ANAEMIA IN PREGNANCY AHMED ABDULWAHAB. It is the commonest medical disorder of pregnancy. It is the commonest medical disorder of pregnancy. Physiological.
ERYTHROPOIESIS- STIMULATING AGENTS. Patients who are no longer able to produce enough erythropoietin in the kidneys may benefit from treatment with.
AGENTS FOR MEGALOBLASTIC ANEMIAS. Megaloblastic anemia is treated with folic acid and vitamin B12. Folate deficiencies usually occur secondary to increased.
AGENT FOR SICKLE CELL ANEMIA
 The ARBs include the following drugs:  azilsartan (Edarbi),candesartan (Atacand), eprosartan (Teveten), irbesartan(Avapro), losartan (Cozaar), olmesartan.
Kidney Failure. Functions of the Kidney n Remove waste products and excess fluid n Produce hormones and vitamins n Help regulate blood pressure n Produce.
Chapter 22 Agents Used to Treat Anemias. Anemia p526 Decrease in hemoglobin or decrease in RBCs Many causes of anemia – Iron deficiency anemia – Chemotherapy.
Iron Deficiency Anemia Iron Metabolism: Iron Metabolism: IRON INTAKE (Dietary) - “ average ” adult diet = mg Fe/day - absorption = 5-10% (0.5-2 mg/day)
TREATMENT IRON DEFICIENCY ANEMIA. 3 Approaches in the Treatment of IDA: 1.Red Cell Transfusion 2.Oral Iron Therapy 3.Parenteral Iron Therapy Braunwald.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 11 Miscellaneous Anti-Infectives.
Principles of Drug Action
Donepezil. Donepezil Generic name: Donepezil. Brand name: Aricept. Chemistry: Donepezil hydrochloride is a piperidine derivative. It is a white crystalline.
Foundation Knowledge and Skills
Thalassemia Center 1 Iron Overload in Chronic Anaemias.
Hematologic Problems Klecka, Spring 2016.
Haematinic Drugs Course: Pharmacology I Course Code: PHR 213 Course Instructor: Md. Samiul Alam Rajib Senior Lecturer Department of Pharmacy BRAC University.
Drugs Used in Anemia.
ROLE OF IRON IN HEALTH AND DISEASE
Life Span Consideration
Factors Affecting Drug Activity
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Factors affecting Drug Activity
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Drugs Used in Anemia.
Other Protein Synthesis Inhibitor
Pharmacokinetics and Factors of Individual Variation
Clinical pharmacy laboratory/4 th Class Anemias and blood disorders
Microminerals (trace elements) Iron
Metabolism of iron Alice Skoumalová.
IRON IN HEALTH AND DISEASE Enterocyte Gut ABSORPTION OF IRON Fe+++ Ferritin Fe++ Tf-Fe+++ Fe++ Haem Tf.
Presentation transcript:

AGENTS USED FOR IRON DEFICIENCY ANEMIA

Although most people get all of the iron they need through diet, in some situations diet alone may not be adequate. The iron preparations that are available include ferrous fumarate (Feostat), ferrous gluconate (Fergon), ferrous sulfate (Feosol), ferrous sulfate exsiccated (Feratab, Slow FE), ferumoxytol (Feraheme), iron dextran (InFeD), iron sucrose (Venofer), and sodium ferric gluconate complex (Ferrlecit).

Therapeutic Actions and Indications They are indicated for the treatment of iron deficiency anemias and may also be used as adjunctive therapy in patients receiving an erythropoiesis-stimulating drug.

Pharmacokinetics Ferrous fumarate, ferrous gluconate, ferrous sulfate, and ferrous sulfate exsiccated are available for oral administration. Iron dextran is a parenteral form of iron given by the Z-track method, which may be used if an oral form cannot be given or cannot be tolerated. Patients with severe GI absorption problems may require this form of iron.

Patients should be switched to the oral form if at all possible because of the pain associated with intramuscular (IM)administration of iron. Iron sucrose, ferumoxytol and sodium ferric gluconate complex are given intravenously specifically for patients who are undergoing chronic hemodialysis or who are in renal failure and not on dialysis but are receiving supplemental erythropoietin therapy.

Iron is primarily absorbed from the small intestine by an active transport system. It is transported in the blood, bound to transferrin. Small amounts are lost daily in the sweat, urine, sloughing of skin and mucosal cells, and sloughing of intestinal cells, as well as in the menstrual flow of women. Most of the oral drug that is taken is lost in the feces, but slowly some of the metal is absorbed into the intestine and transported to the bone marrow. It can take 2 to 3 weeks to see improvement and up to 6 to 10 months for a return to a stable iron level once a deficiency exists. It is used during pregnancy and lactation to help the mother meet the increased demands for iron that occur at those times.

Contraindications and Cautions These drugs are contraindicated for patients with known allergy to any of these preparations because severe hypersensitivity reactions have been associated with the parenteral form of iron. They also are contraindicated in the following conditions: hemochromatosis (excessive iron);hemolytic anemias, which may increase serum iron levels and cause toxicity; normal iron balance because the drug will not be absorbed and will just pass through the body;and peptic ulcer, colitis, or regional enteritis because the drug can be directly irritating to these tissues and can cause exacerbation of the diseases.

Adverse Effects The most common adverse effects associated with oral iron are related to direct GI irritation; these include GI upset, anorexia, nausea, vomiting, diarrhea, dark stools,and constipation. With increasing serum levels, iron can be directly toxic to the CNS, causing coma and even death.

Parenteral iron is associated with severe anaphylactic reactions, local irritation,staining of the tissues, and phlebitis. Ferumoxytol is a supermagnetic iron oxide that can alter MRI images and interpretation for up to 3 months after administration;patients should be aware that they have been given this drug and cautioned to report it before undergoing any medical testing.

Chelating Agents Heavy metals, including iron, lead, arsenic, mercury,copper, and gold, can cause toxicity in the body by their ability to tie up chemicals in living tissues that need to be free in order for the cell to function normally. When these vital substances (thiols, sulfurs, carboxyls, and phosphoryls)are bound to the metal, certain cellular enzyme systems become deactivated, resulting in failure of cellular function and eventual cell death. Drugs that have been developed to counteract metal toxicity are called chelating agents (from the Greek word for “claw”).

Chelating agents grasp and hold a toxic metal so that it can be carried out of the body before it has time to harm the tissues. The chelating agent binds the molecules of the metal, preventing it from damaging the cells within the body. The complex that is formed by the chelating agent and the metal is nontoxic and is excreted by the kidneys.

Clinically Important Drug–Drug Interactions Iron absorption decreases if iron preparations are taken with antacids, tetracyclines, or cimetidine; if these drugs must be used, they should be spaced at least 2 hours apart. Anti-infective response to ciprofloxacin, norfl oxacin,or ofl oxacin can decrease if these drugs are taken with iron because of a decrease in absorption; they also should be administered at least 2 hours apart. Increased iron levels occur if iron preparations are taken with chloramphenicol; patients receiving this combination should be monitored closely for any sign of iron toxicity. The effects of levodopa may decrease if it is taken with iron preparations; patients receiving both of these drugs should take them at least 2 hours apart.

Clinically Important Drug–Food Interactions Iron is not absorbed if taken with antacids, eggs, milk, coffee, or tea. These substances should not be administered concurrently. Acidic liquids may enhance the absorption of iron and should be not be given concurrently.